• All Topics
  • Health Technology Assessment (HTA)
  • Antimicrobial Resistance (AMR)
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real-World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme
  • IRA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

  • Health Technology Assessment…
  • Israel

NICE enough? Do NICE’s Decision Outcomes Impact International HTA Decision-making?

andrew-butler-aUu8tZFNgfM-unsplash
Read more
  • Health Technology Assessment…
  • Value, Affordability, and…
  • Gene therapies

Are Recommendations for HTA of Gene Therapies Being Achieved?

cover 3
Read more
  • Chronic Diseases
  • Value, Affordability, and…
  • Dermatology

The Burden of Hidradenitis Suppurativa on Patients, the NHS and Society

jakob-braun-HfOOKAPsE28-unsplash
Read more
  • Digital Health
  • Economics of Innovation
  • Mental Health

Dementia in the UK: Estimating the Potential Future Impact and Return on Research Investment

image option 1
Read more
  • Precision Medicine
  • Economics of Innovation

The Case for Expanding Uptake of Next-Generation Sequencing for Lung Cancer in Europe

NGS report_AdobeStock_406823942_portrait
Read more
  • Antimicrobial Resistance (AMR)
  • Economics of Innovation

A Novel Incentive Model for Uptake of Diagnostics to Combat Antimicrobial Resistance

Roche AMR diangostics_national-cancer-institute-2fyeLhUeYpg-unsplash_portrait
Read more
  • Health Technology Assessment…
  • Value, Affordability, and…
  • Pricing and Reimbursement

Real-World Evidence: Current Best Practice for Reimbursement Decision-Making

RWE_clay-banks-b5S4FrJb7yQ-unsplash_portrait
Read more
  • Value-Based Pricing
  • Economics of Innovation
  • Pricing and Reimbursement

Delivering the Triple Win: A Value-Based Approach to Pricing

Triple_Win_AdobeStock_249059909_portrait_v2
Read more
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real-World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • IRA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • Insight
11 min read 5th February 2018

Alan Maynard – Alas No More

Tony Culyer writes on the contribution to health economics of Alan Maynard, the pioneering health economist, who died on February 2nd 2018. If you wanted to know what people thought of Alan Maynard, the pioneering health economist, and why they…

Share:
  •  Twitter
  •  LinkedIn
  •  Facebook
  • has-icon Email

Tony Culyer writes on the contribution to health economics of Alan Maynard, the pioneering health economist, who died on February 2nd 2018.

If you wanted to know what people thought of Alan Maynard, the pioneering health economist, and why they thought it, you could not do better than to pick up a little yellow paperback book called Maynard Matters – Critical Thinking on Health Policy which will tell you nearly all you need to know about him and why he mattered.

He will be chiefly remembered as an uncompromising rubber of other people’s noses (especially those belonging to doctors, politicians and health service managers) in the ineluctable truths of economics. His economics was not over-sophisticated and he never blinded innocent mind with maths or weighty abstractions. Simple mainstream economic points, well-made, empirically bolstered, forcefully (often ironically) expressed and insightfully applied to serious problems – these are the hallmarks of classic Maynard the window-breaker (not my phrase but Virginia Bottomley’s – consult the yellow paperback). He could coin a phrase. My favourite is “NHS redisorganisation”, a very handy neologism for all students of health care in the UK. These talents made him a brilliant teacher. I can’t imagine anyone sleeping through an Alan Maynard lecture.

But. (There’s a good one-word sentence for you.) Look at that yellow paperback. The first half of it tells you what others thought of him. The second tells you what he thought – about regional inequalities in the NHS, putting the economics in evidence informed medicine where Cochrane and Sackett had stopped short, resisting the narrowing perspective of “health economics” as it tended to become identified with “cost-effectiveness analysis”, addiction and policies for behaviour change, manpower (as was once said) planning and role substitution in the clinical professions, misdirected training in public health management skills, redirecting policy focus from inputs to outputs, the need for rational rationing, competition and choice in the NHS, avoiding misplaced market idolatry, NHS disorganisation and redisorganisation, fallacious international comparisons of healthcare systems, general practice fund-holding, and sensible regulation of pharmaceuticals.

Nearly all of his writing across this wide portfolio of topics appeared in accessible places – most notably the Health Service Journal – that were not exclusively where economists write for economists. This was his greatest gift: to be able to summarise large literatures in approachable language with eagle-eyed targeting and dollops of irony to discomfort the complacent. It wasn’t his only gift. He also made notable contributions to the material summarised. He founded the Centre for Health Economics at York and nurtured it into an internationally dominant position. He directed the first UK Masters programme in health economics at York, which can convincingly claim still to be the world leader. He taught countless students and won and undertook dozens (possibly hundreds) of research grants. He was an indefatigable lecturer throughout the UK and abroad. He was a generous helper and supporter of other university centres of health economics expertise (notably Aberdeen, from which he had an honorary doctorate). He was a committed Chair of York Hospital for twelve years and of the Vale of York NHS Commissioning Group for four until his health began to fail. He received an OBE for his service to the NHS.

In these days, when academic merit is increasingly being reckoned in terms of “impact”, he surely stands alone as an outstanding health economist who really did make a difference.

Read the full obituary here.

Alan Maynard gave the 2013 OHE Annual Lecture on Contracting for Quality in the NHS.

Related Insights

HTA Slovak Republic-1
  • Insight
  • September 2023

Around The World in HTAs: The Slovak Republic – Valuing the Future

Read more
Beige Minimalist Timeline Diagram Graph
  • Insight
  • August 2023

The changing role of the NHS over time

Read more
this one
  • Insight
  • July 2023

Around The World in HTAs: Egypt – The Road Ahead

Read more
NHS 75 Insight 1_life expectancy at birth
  • Insight
  • July 2023

Can a continued focus on prevention, diagnosis, and treatment see the NHS to another 75 years?

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for OHE Insights, Events & News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for OHE Insights, Events & News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in .

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!